close 74% rachunków inwestorów detalicznych odnotowuje straty w wyniku handlu kontraktami CFD u niniejszego dostawcy. Inwestowanie wiąże się z ryzykiem i nie jest odpowiednie dla wszystkich inwestorów. Kontrakty CFD są złożonymi instrumentami i wiążą się z dużym ryzykiem szybkiej utraty środków pieniężnych z powodu dźwigni finansowej. 74% rachunków inwestorów detalicznych odnotowuje straty w wyniku handlu kontraktami CFD u niniejszego dostawcy. Upewnij się, czy rozumiesz, jak działają kontrakty CFD, i czy możesz pozwolić sobie na wysokie ryzyko utraty pieniędzy.
Change languagePolski
Pulpit

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Strona główna・Stock List・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Closed

SectorHealthcare

8.32 -0.24

Strong Buy

Price update 18 mar 2026, 19:58 UTC

BuySell

Overview

Share price change

24h

Current

Min

7.86

Max

8.54

Key metrics

By Trading Economics

Income

-69M

-102M

Sales

-10M

34M

EPS

-5.69

Profit margin

-299.886

Employees

228

EBITDA

4.7M

-18M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+132.7% upside

Market Stats

By TradingEconomics

Market Cap

-267K

157M

Previous open

8.56

Previous close

8.32

News Sentiment

By Acuity

34%

66%

97 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

5.9501 / 7.66 Support & Resistance

Karyopharm Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 mar 2026, 22:51 UTC

Earnings

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

DJ

Read

18 mar 2026, 21:40 UTC

Acquisitions, Mergers, Takeovers

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

DJ

Read

18 mar 2026, 20:31 UTC

Earnings

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

DJ

Read

18 mar 2026, 23:49 UTC

Market Talk
Major News Events

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

DJ

Read

18 mar 2026, 23:31 UTC

Market Talk

Gold Rises on Likely Technical Recovery -- Market Talk

DJ

Read

18 mar 2026, 22:49 UTC

Market Talk

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

DJ

Read

18 mar 2026, 22:41 UTC

Market Talk

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

DJ

Read

18 mar 2026, 22:36 UTC

Earnings

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

DJ

Read

18 mar 2026, 22:24 UTC

Earnings

AIA Group Announces New Share Buyback of $1.7B >1299.HK

DJ

Read

18 mar 2026, 22:23 UTC

Earnings

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

DJ

Read

18 mar 2026, 22:23 UTC

Earnings

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

DJ

Read

18 mar 2026, 21:58 UTC

Earnings

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

DJ

Read

18 mar 2026, 21:55 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

DJ

Read

18 mar 2026, 21:55 UTC

Market Talk
Earnings

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

DJ

Read

18 mar 2026, 21:40 UTC

Market Talk

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

DJ

Read

18 mar 2026, 21:16 UTC

Market Talk

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

DJ

Read

18 mar 2026, 21:00 UTC

Major News Events

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

DJ

Read

18 mar 2026, 20:58 UTC

Earnings

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

DJ

Read

18 mar 2026, 20:41 UTC

Earnings

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

DJ

Read

18 mar 2026, 20:29 UTC

Earnings

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

DJ

Read

18 mar 2026, 20:25 UTC

Earnings

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

DJ

Read

18 mar 2026, 20:17 UTC

Earnings

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

DJ

Read

18 mar 2026, 20:14 UTC

Market Talk

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

DJ

Read

18 mar 2026, 20:09 UTC

Earnings

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

DJ

Read

18 mar 2026, 20:07 UTC

Earnings

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

DJ

Read

18 mar 2026, 20:06 UTC

Earnings

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

DJ

Read

18 mar 2026, 20:04 UTC

Earnings

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

DJ

Read

18 mar 2026, 20:04 UTC

Earnings

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

DJ

Read

18 mar 2026, 20:04 UTC

Earnings

Micron Technology Sees 3Q Gross Margin About 81% >MU

DJ

Read

18 mar 2026, 20:03 UTC

Earnings

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

DJ

Read

Peer Comparison

Price change

Karyopharm Therapeutics Inc Forecast

Price Target

By TipRanks

132.7% upside

12 Months Forecast

Average 19.5 USD  132.7%

High 28 USD

Low 12 USD

Based on 5 Wall Street analysts offering 12 month price targets forKaryopharm Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Based on 5 analysts giving stock ratings to Karyopharm Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.9501 / 7.66Support & Resistance

Short Term

Bullish Evidence

Recent bullish events outweigh bearish events.

Intermediate Term

Strong Bearish Evidence

All events are bearish.

Long Term

No Evidence

There are no events.

Sentiment

By Acuity

97 / 351 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

Other stocks from the sector

LLY

Eli Lilly and Co.

916.49

↓-1.52%

JNJ

Johnson and Johnson

237.15

↓-0.37%

ABBV

AbbVie Inc

208.28

↓-5.27%

NVS

Novartis AG

149.76

↓-3.06%

AZN

AstraZeneca PLC

188.42

↓-1.47%
help-icon Live chat